• Japanese
  • Korean
  • Chinese
Cover Image

Anxiety Disorders

Abstract

Description

This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi, UCB SA, Valeant Pharmaceuticals International, and Watson Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
    • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
    • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Anxiety Disorders: A Prelude
  • Future Outlook - Market Challenged by Generics and Efficacy Issues
  • A Snapshot of the Global Market Opportunity
  • Prevalence of Specific Anxiety Disorders
    • Generalized Anxiety Disorder (GAD)
    • Obsessive-Compulsive Disorder (OCD)
    • Specific Phobias
    • Social Phobias
    • Panic Disorder
    • Post Traumatic Stress Disorder (PTSD)
    • Social Anxiety Disorder (SAD)
  • Anxiety Disorders Can Strike At Any Age
    • Shyness: A Form of Anxiety Disorder among Kids and Teenagers
    • Table 1: Average Age of Onset for Select Anxiety Disorders (includes corresponding Graph/Chart)
  • Women - The Most Affected Lot with Anxiety
    • Table 2: Female to Male Ratio for Incidence of Anxiety Disorders by Type of Disorder (includes corresponding Graph/Chart)
  • Patent Expiries - A Major Impediment to Market Growth
  • Patent Expiries of Select Leading Drugs Indicated for Anxiety Disorders
  • Leading Drugs and Indications for Anxiety Disorders

2. PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS

  • Pharmacological Treatment
  • Available Treatment for Anxiety Disorders - In a Nutshell
  • Antidepressants for Anxiety Disorders
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Zoloft (Sertraline)
    • Paxil (Paroxetine)
    • Prozac (Fluoxetine)
    • Cipralex/Lexapro (Escitalopram)
    • Competitive Scenario - Cymbalta Emerges as a Market Leader in Anti-Depressants Market
    • Table 3: Select Leading Anti-Depressants indicated for Anxiety Disorders (2007-2009): Annual Revenues for Cymbalta, Lexapro, Paxil & Wellbutrin, Effexor, Zoloft, and Remeron in US$ Million (includes corresponding Graph/Chart)
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
    • Cymbalta (Duloxetine)
    • Effexor (Venlafaxine)
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Tricyclic and Tetracyclic Antidepressants (TCAs)
  • Other Antidepressants
  • Sedatives
  • Benzodiazepines (BZDs)
  • Other Medications
  • Obsessive Compulsive Disorder (OCD) Treatment
    • Table 4: Dosing of Select Serotonin Reuptake Inhibitors in OCD Treatment
  • Generalized Anxiety Disorder (GAD) Treatment
  • Drugs Indicated for the Treatment of Generalized Anxiety Disorder (GAD)
  • Novel Therapies for GAD on the Anvil
    • Novel Compounds Under Investigation for Generalized Anxiety Disorder (GAD)

3. DRUG PIPELINE ANALYSIS

  • Select Anti-Anxiety Pipeline Drugs in Phase III Development Stage and Filed for Approval
  • Select Anti-Anxiety Pipeline Drugs in Phase II Development Stage
  • Select Anti-Anxiety Pipeline Drugs in Phase I Development Stage

4. NON-PHARMACOLOGICAL TREATMENT

  • Psychological Treatment
  • Cognitive Behavioral Therapy
  • Relaxation Techniques
  • Biofeedback
  • Hypnotherapy
  • Meditation
  • Natural Remedies for Treating Anxiety
  • Acupuncture
  • Other Treatment Options
  • Support Program
  • Changes in Lifestyle

5. ANXIETY DISORDERS - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS

  • What is Anxiety Disorder?
  • Types of Anxiety Disorders
  • A Review of Anxiety Disorders
  • Generalized Anxiety Disorder (GAD)
  • Panic Disorder
  • Phobias
    • Agoraphobia
    • Social Phobia
  • Obsessive-Compulsive Disorder (OCD)
    • Symptoms, Obsessions and Compulsions of Obsessive-Compulsive Disorder
  • Particular Phobic Anxiety Disorder (PPAD)
  • Post-Traumatic Stress Disorder (PTSD)
  • Separation Anxiety Disorder (SAD)
  • Anxiety Disorders in Children
  • Anxiety Disorders in Teens
  • Causes and Factors for Anxiety Disorder
  • Symptoms
  • Diagnosis for Anxiety Disorders

6. PRODUCT APPROVALS AND LAUNCHES

  • Sun Pharma Receives FDA Approval to Commercialize Generic Cymbalta
  • Impax Receives Tentative FDA Approval for Generic Version of Cymbalta
  • Actavis Receives FDA Approval for Alprazolam
  • Sun Pharma Receives FDA Approval to Generic Version of Alprazolam
  • Bafna Pharmaceuticals Receives Approval for Anxiety Drug in UK
  • Coenzyme-A Technologies Introduces MODULATOR MATRIX I
  • Sun Pharma to Launch Generic Version of Venlafaxine
  • Eli Lilly Receives FDA Approval for Cymbalta for Treating GAD
  • Aurobindo Pharma Receives Tentative US FDA Approval for Escitalopram
  • Boehringer Ingelheim and Eli Lilly Obtain Approval for Cymbalta in Canada
  • Medtronic's Reclaim Deep Brain Stimulation Therapy Receives CE-Mark Approval
  • Otsuka Pharmaceutical and BMS Obtain FDA Approval for sNDA
  • Servier Obtains EMEA Approval for Valdoxan in Treating Major Depressive Episodes
  • Boehringer Ingelheim and Eli Lilly Receive EU Approval for Cymbalta in GAD
  • AstraZeneca Files for Approval of Seroquel XR for GAD in Europe
  • Glenmark Pharmaceuticals Launches Hydroxyzine Hydrochloride Tablets
  • Jazz Pharma Launches Once-A-Day LUVOX® CR Extended-Release Capsules

7. RECENT INDUSTRY ACTIVITY

  • Euthymics Acquires DOV Pharma
  • Abbott Acquires Solvay Pharmaceuticals
  • Pfizer Withdraws sNDA for Lyrica in Treating GAD
  • Eli Lilly Drags Sun Pharma to Court for Alleged Infringment of Cymbalta Patent
  • Pfizer Discontinues Late Stage Development of GAD Drug Candidate
  • Pacgen Biopharmaceuticals Acquires Xphase Pharmaceuticals
  • GSK Inks Agreement for Divesting Wellbutrin XL® Rights to Biovail International
  • Ligand Pharmaceuticals Acquires Neurogen
  • FDA Seeks Additional Information for Seroquel XR sNDA in GAD Treatment
  • AstraZeneca's Seroquel XR™ Shows Improvement in GAD Symptoms
  • Synosia Therapeutics Begins Phase II Efficacy Trial for Rufinamide
  • Ambien CR® Improves Chronic Insomnia in Patients with Co-morbid GAD
  • AstraZeneca Files sNDA for Seroquel XR for Treating GAD
  • Bionomics Concludes GMP Synthesis of BNC210
  • OJSC Pharmstandard to Take Over Afobazol® Trademark

8. FOCUS ON SELECT GLOBAL PLAYERS

  • AstraZeneca Plc. (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Forest Laboratories, Inc. (US)
  • GlaxoSmithKline Plc. (UK)
  • H. Lundbeck A/S (Denmark)
  • Mylan, Inc. (US)
  • Neurocrine Biosciences, Inc. (US)
  • Pfizer, Inc. (US)
  • Ratiopharm (Germany)
  • Sanofi (France)
  • UCB SA (Belgium)
  • Valeant Pharmaceuticals International (US)
  • Watson Laboratories, Inc. (US)

9. GLOBAL MARKET PERSPECTIVE

    • Table 5: World Recent Past, Current and Future Analysis for Anxiety Disorders by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 6: World Historic Review for Anxiety Disorders by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 7: World 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Anxiety Disorders - A Major Health Burden
    • Prevalence of Anxiety Disorders
    • Table 8: US Prevalence of Anxiety Disorders by Type (includes corresponding Graph/Chart)
    • Product Approvals and Launches
    • Strategic Corporate Developments
    • Select Players
      • Bristol-Myers Squibb Company
      • Eli Lilly and Company
      • Forest Laboratories, Inc.
      • Mylan, Inc.
      • Neurocrine Biosciences, Inc.
      • Pfizer, Inc.
      • Valeant Pharmaceuticals International
      • Watson Laboratories, Inc.
  • B. Market Analytics
    • Table 9: The US Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 10: The US Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2. EUROPE

  • A. Market Analysis
    • Product Approval
  • B. Market Analytics
    • Table 11: European Recent Past, Current & Future Analysis for Anxiety Disorders by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 12: European Historic Review for Anxiety Disorders Market by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 13: European 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2a. FRANCE

  • A. Market Analysis
    • Clinical Trials/Product Approvals
    • Select Player
  • B. Market Analytics
    • Table 14: French Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 15: French Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2b. GERMANY

  • A. Market Analysis
    • Product Approval
    • Select Players
  • B. Market Analytics
    • Table 16: German Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 17: German Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2c. ITALY

  • A. Market Analysis
    • Select Player
      • Polifarma SpA
  • B. Market Analytics
    • Table 18: Italian Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 19: Italian Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2d. THE UNITED KINGDOM

  • A. Market Analysis
    • An Overview of the Market Opportunity
    • Table 20: Prevalence of Depression and Anxiety Disorders in the UK (2006): Percentage of Adult Population (16-75 Years) Affection by Condition (includes corresponding Graph/Chart)
    • Product Approvals/Clinical Trials
    • Select Players
  • B. Market Analytics
    • Table 21: The UK Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 22: The UK Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2e. SPAIN

  • Market Analytics
    • Table 23: Spanish Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 24: Spanish Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2f. REST OF EUROPE

  • A. Market Analysis
    • Strategic Corporate Development
    • Select Players
  • B. Market Analytics
    • Table 25: Rest of European Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 26: Rest of European Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3. ASIA-PACIFIC

  • A. Market Analysis
    • Anxiety and Depression - A Major Debilitating Condition in Australia
    • Table 27: 12-Month Prevalence of Anxiety Disorders in Australia by Age Group (2006) (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Select Player
  • B. Market Analytics
    • Table 28: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 29: Asia-Pacific Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Product Approval
    • Select Player
      • Ranbaxy Egypt Ltd. (Egypt)
  • B. Market Analytics
    • Table 30: Rest of World Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 31: Rest of World Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Show More
Pricing
Get Notified
Email me when related reports are published